<DOC>
	<DOCNO>NCT00826436</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability ascending , multiple , oral dos PRA-027 Japanese postmenopausal woman . The secondary purpose evaluate PK PD profile multiple oral dos PRA-027 Japanese postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Pharmacokinetics Pharmacodynamics PRA-027 Japanese Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Aged 35 65 year inclusive study day 1 treatment period . Menopause may spontaneous due surgery . Postmenopausal woman define follow : Spontaneous amenorrhea must begin age 55 year . Spontaneous amenorrhea must initiate least 6 month study day 1 treatment period . For subject spontaneous amenorrhea least 6 month le 12 month screen , folliclestimulating hormone ( FSH ) level must ≥ 38 mIU/mL . For subject spontaneous amenorrhea 12 month longer screen , FSH level determination require . For subject amenorrhea result bilateral oophorectomy without hysterectomy ; surgery must occur least 6 month screen . No FSH measurement require . Subjects must provide evidence procedure operative report ultrasound scan . The date ( month/year ) subject ' last menstrual period must determine record source document . 2 . Body mass index ( BMI ) range 17.6 26.4 kg/m2 bodyweight ≥ 45 kg . BMI calculate take subject 's weight , kilogram , divide square subject 's average height , meter , screening : BMI = weight ( kg ) / [ Height ( ) ] 2 3 . Healthy , determine investigator , basis screening evaluation . 4 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine level upper limit normal screening . 5 . Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay . 6 . Have high probability compliance completion study . EXCLUSION CRITERIA : 1 . Presence history disorder may prevent successful completion study . 2 . Any significant cardiovascular , hepatic , renal , respiratory , gynecologic , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . Women asymptomatic leiomyomata may enrol study . 3 . Women undergone hysterectomy . 4 . Women complex simple ovarian cyst great 3 cm indiameter . 5 . Any surgical medical condition may interfere absorption , distribution , metabolism , excretion test article ( eg , resection liver , kidney , gallbladder , gastrointestinal tract ) . 6 . Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day receive test article ( treatment period study day 1 ) . 7 . History drug abuse . 8 . Admitted alcohol abuse history alcohol use may interfere subject 's ability comply protocol requirement . 9 . History presence polycystic ovarian disease . 10 . History female infertility . 11 . History family history arterial venous thrombosis . 12 . Any clinically significant deviation normal limit result physical examination , vital sign measurement , 12lead electrocardiogram ( ECGs ) , clinical laboratory test . 13 . Demonstration positive finding orthostatic test screening . The definition positive finding ≥20 mm Hg decrease systolic blood pressure , ≥ 10 mm Hg decrease diastolic blood pressure , ≥ 30 bpm increase pulse , stand 3 minute . 14 . Positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . 15 . Positive finding urine drug screening ( eg , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates phencyclidine [ PCP ] ) . 16 . History clinically important drug allergy adverse drug reaction ( eg , relapse dermatitis , drug hypersensitivity , drug allergy , hypersensitivity ingredient test article , angioedema ) 17 . Use investigational prescription drug within 90 day receive test article ( treatment period day 1 ) prescription drug within 30 day study day 1 . 18 . Consumption caffeinecontaining product ( eg , coffee , tea , chocolate , carbonate beverage ) alcoholic beverage within 48 hour receive test article ( treatment period day 1 ) . 19 . Consumption grapefruit grapefruitcontaining product within 72 hour study day 1 ( treatment period day 1 ) . 20 . Use overthecounter drug , include herbal supplement ( except use vitamin ≤ 100 % recommend daily allowance ) , within 14 day receive test article ( treatment period day 1 ) . 21 . Donation blood within 90 day study day 1 . 22 . Subjects deem investigator inappropriate accord inclusion study .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>